Eli Lilly has chalked up another victory in the chronic lymphocytic leukemia space, as its BTK inhibitor Jaypirca delivered its fourth positive phase 3 readout in the blood cancer, this time as an industry first. More: Lilly’s Jaypirca shows fixed-duration
read more
Company expects two‑year dfs data by q1 2028 More: Transgene completes randomisation in phase 2 trial of tg4050 Source: News
read more
New authorisation offers additional option for patients with lvef ≥40% More: Bayer wins MHRA approval for Kerendia in heart failure Source: News
read moreGSK and Shionogi’s ViiV Healthcare is seeking to raise awareness around what the company sees as a forgotten element in HIV: young people with the infection. More: ViiV launches ‘Still Here’ campaign aimed at reminding young people about HIV Source:
read moreWith its latest obesity play appearing to pay off, Regeneron has turned its attention to radiopharmaceuticals. More: Regeneron rides into radiopharma via .1B biobucks pact with Australia’s Telix Source: fierce
read moreHHS secretary Robert F. Kennedy Jr. is continuing to reshape the CDC’s Advisory Committee on Immunization Practices in a way that’s setting off alarm bells for some experts. More: HHS, after legal setback, updates ACIP charter to put more emphasis
read more© 1994 - 2026 B.M. Pharmaceuticals